Pages that link to "Q37269261"
Jump to navigation
Jump to search
The following pages link to Differential response to neoadjuvant chemotherapy among 7 triple-negative breast cancer molecular subtypes (Q37269261):
Displaying 50 items.
- The hedgehog pathway in triple-negative breast cancer (Q26740373) (← links)
- Of mice and women: a comparative tissue biology perspective of breast stem cells and differentiation (Q26796835) (← links)
- Clinical implications of the intrinsic molecular subtypes of breast cancer (Q26800996) (← links)
- Novel treatment strategies in triple-negative breast cancer: specific role of poly(adenosine diphosphate-ribose) polymerase inhibition (Q26851765) (← links)
- Targeting the androgen receptor in prostate and breast cancer: several new agents in development (Q27009424) (← links)
- Epidemiology, biology, and treatment of triple-negative breast cancer in women of African ancestry (Q27011535) (← links)
- Molecular Classification of Triple-Negative Breast Cancer (Q28076661) (← links)
- Breast cancer molecular subtypes: from TNBC to QNBC (Q28076805) (← links)
- Concepts and targets in triple-negative breast cancer: recent results and clinical implications (Q28078992) (← links)
- Tailoring therapies--improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015 (Q28085062) (← links)
- Predictive biomarkers for triple negative breast cancer treated with platinum-based chemotherapy (Q33441772) (← links)
- Aptamer-mediated impairment of EGFR-integrin αvβ3 complex inhibits vasculogenic mimicry and growth of triple-negative breast cancers (Q33582972) (← links)
- Genes associated with histopathologic features of triple negative breast tumors predict molecular subtypes (Q33589487) (← links)
- Gene regulatory pattern analysis reveals essential role of core transcriptional factors' activation in triple-negative breast cancer (Q33591757) (← links)
- Targeting oncogenic vulnerabilities in triple negative breast cancer: biological bases and ongoing clinical studies (Q33591876) (← links)
- Tumor Sequencing and Patient-Derived Xenografts in the Neoadjuvant Treatment of Breast Cancer (Q33614238) (← links)
- Androgen Receptor as a Potential Target for Treatment of Breast Cancer (Q33625672) (← links)
- Prognostic Evaluation of Epidermal Growth Factor Receptor (EGFR) Genotype and Phenotype Parameters in Triple-negative Breast Cancers (Q33646271) (← links)
- Open-label randomized clinical trial of standard neoadjuvant chemotherapy with paclitaxel followed by FEC versus the combination of paclitaxel and everolimus followed by FEC in women with triple receptor-negative breast cancer†. (Q33683126) (← links)
- Characterizing Breast Cancer in a Population with Increased Prevalence of Triple-Negative Breast Cancer: Androgen Receptor and ALDH1 Expression in Ghanaian Women (Q33697429) (← links)
- Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease (Q33769821) (← links)
- Precision medicine in breast cancer: reality or utopia? (Q33809114) (← links)
- Phytochemicals potently inhibit migration of metastatic breast cancer cells (Q33810248) (← links)
- Trp63 is regulated by STAT5 in mammary tissue and subject to differentiation in cancer. (Q33815791) (← links)
- Breast Cancer and African Ancestry: Lessons Learned at the 10-Year Anniversary of the Ghana-Michigan Research Partnership and International Breast Registry (Q33859719) (← links)
- Pathological features of triple-negative breast cancers that showed progressive disease during neoadjuvant chemotherapy (Q33873330) (← links)
- Identification and use of biomarkers in treatment strategies for triple-negative breast cancer subtypes (Q33874621) (← links)
- Prevalence and predictors of androgen receptor and programmed death-ligand 1 in BRCA1-associated and sporadic triple-negative breast cancer (Q33915040) (← links)
- The molecular landscape of high-risk early breast cancer: comprehensive biomarker analysis of a phase III adjuvant population (Q33915044) (← links)
- Triple-negative breast cancer: the importance of molecular and histologic subtyping, and recognition of low-grade variants (Q33915057) (← links)
- PIK3CA mutations in androgen receptor-positive triple negative breast cancer confer sensitivity to the combination of PI3K and androgen receptor inhibitors (Q34296476) (← links)
- Predicting response and survival in chemotherapy-treated triple-negative breast cancer. (Q34354538) (← links)
- Tumor-infiltrating CD8 and FOXP3 lymphocytes in triple-negative breast cancer: its correlation with pathological complete response to neoadjuvant chemotherapy (Q34447829) (← links)
- Is the future of personalized therapy in triple-negative breast cancer based on molecular subtype? (Q34476337) (← links)
- BCL-2, topoisomerase IIα, microvessel density and prognosis of early advanced breast cancer patients after adjuvant anthracycline-based chemotherapy (Q34491903) (← links)
- Predictors of Chemosensitivity in Triple Negative Breast Cancer: An Integrated Genomic Analysis (Q34547261) (← links)
- Standard of care and promising new agents for triple negative metastatic breast cancer (Q34774884) (← links)
- Pharmacological profiling of kinase dependency in cell lines across triple-negative breast cancer subtypes (Q34978420) (← links)
- Pathologic response prediction to neoadjuvant chemotherapy utilizing pretreatment near-infrared imaging parameters and tumor pathologic criteria (Q35000348) (← links)
- Oncogenic signaling in amphiregulin and EGFR-expressing PTEN-null human breast cancer (Q35007438) (← links)
- Androgen receptor status is a prognostic marker in non-basal triple negative breast cancers and determines novel therapeutic options (Q35088745) (← links)
- Tumor Infiltrating Lymphocytes - The Next Step in Assessing Outcome and Response to Treatment in Patients with Breast Cancer (Q35149726) (← links)
- Gene-expression molecular subtyping of triple-negative breast cancer tumours: importance of immune response (Q35314135) (← links)
- Phase II Study of Gemcitabine, Carboplatin, and Iniparib As Neoadjuvant Therapy for Triple-Negative and BRCA1/2 Mutation-Associated Breast Cancer With Assessment of a Tumor-Based Measure of Genomic Instability: PrECOG 0105 (Q35671356) (← links)
- Comprehensive Two- and Three-Dimensional RNAi Screening Identifies PI3K Inhibition as a Complement to MEK Inhibitor AS703026 for Combination Treatment of Triple-Negative Breast Cancer (Q35861891) (← links)
- Metaplastic breast carcinomas display genomic and transcriptomic heterogeneity [corrected]. . (Q35911470) (← links)
- Generation of an algorithm based on minimal gene sets to clinically subtype triple negative breast cancer patients. (Q35933373) (← links)
- Refinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection. (Q36054418) (← links)
- Targeted nanoparticles for image-guided treatment of triple-negative breast cancer: clinical significance and technological advances (Q36157045) (← links)
- Comparison of triple-negative breast cancer molecular subtyping using RNA from matched fresh-frozen versus formalin-fixed paraffin-embedded tissue. (Q36334470) (← links)